Status:
RECRUITING
Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors
Lead Sponsor:
Eye & ENT Hospital of Fudan University
Collaborating Sponsors:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Peking University Third Hospital
Conditions:
Malignant Tumor of Lacrimal Drainage Structure
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The treatment for malignant lacrimal sac tumors is difficult and the prognosis is poor. The conventional strategy is surgical resection followed by adjuvant radiotherapy with or without concurrent che...
Eligibility Criteria
Inclusion
- Patients with suggestive symptoms, signs, imaging features and/or biopsy results for malignant lacrimal sac tumors
- Regardless of previous operations including silicone tube intubation, endoscopic dacryocystorhinostomy and incisional/needle biopsy
Exclusion
- Recurrent tumors
- Metastatic tumors to the lacrimal sac region
- Malignant lacrimal sac tumors with previous surgical excision
- Malignant lacrimal sac tumors with local nodal or distant metastasis
- Special tumor types (e.g. lymphoma) which require non-surgical treatment
- Large tumors (invades ≥ 2/3 depth of the orbit) which require orbital exenteration
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2035
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04016675
Start Date
September 1 2019
End Date
December 31 2035
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan Eye & ENT Hospital
Shanghai, China